A new meta-analysis finds no clear long-term cardiovascular benefit from beta-blockers after myocardial infarction in patients with preserved left ventricular ejection fraction.
Use of beta-blockers has been a cornerstone in the treatment era following acute myocardial infarction (MI), especially in ...
A meta-analysis of recent clinical trials evaluating β-blockers as treatment for patients with acute myocardial infarction ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...
Data provide first human validation of cardiac energetics modulation as a therapeutic target in cardiometabolic heart disease, including heart ...
The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...
Heart failure (HF) substantially impacts the health and financial security of an increasing proportion of the US population. It worsens debility and quality of life and may lead to hospitalization and ...
Heart failure with preserved ejection fraction (HFpEF) is a type of heart failure that affects the left side of the heart. It occurs when the lower left chamber of the heart, called the left ventricle ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback